Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
- Authors
- Cho, Byeong Wook; Kim, Seok Bae; Song, Il Han; Lee, Sae Hwan; Kim, Hong Soo; Lee, Tae Hee; Kang, Young Woo; Kim, Seok Hyun; Lee, Byung Seok; Chae, Hee Bok
- Issue Date
- Mar-2017
- Publisher
- 대한간학회
- Keywords
- Daclatasvir; Asunaprevir; Hepatitis C, Chronic; Korea
- Citation
- Clinical and Molecular Hepatology, v.23, no.1, pp 51 - 56
- Pages
- 6
- Journal Title
- Clinical and Molecular Hepatology
- Volume
- 23
- Number
- 1
- Start Page
- 51
- End Page
- 56
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7771
- DOI
- 10.3350/cmh.2016.0053
- ISSN
- 2287-2728
2287-285X
- Abstract
- Background/Aims: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection. Methods: We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area. Results: A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients. Conclusions: DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7771)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.